Establishing a High Performance, Collaborative & Innovative Medical Affairs Culture at JJIM to accelerate and deliver the depth and breadth of our unrivalled pipeline for patients and their families.Focused on our People, Teams & Culture to unleash our collective potential.

Led and built high performing Haematology-Oncology medical affairs team that delivered transformational launches for patients and the NHS.Rebuilt medical structure from 0 to 35, capabilities and ways of working, clinical collaboration, early forward deployment of medical, the active medical mindset and innovative agile data generation in launch success with world class cross functional collaboration.Therapy areas of focus included ovarian, endometrial, lung, rectal and synovial sarcoma, Multiple Myeloma and Myelofibrosis

Global Medical Leader for first BCMA antibody drug conjugate: Belantamab MafodotinBuilt Multiple Myeloma Global Medical Affairs Team, led medical strategy & unleashed capabilities across: - Medical Strategic Foundation, Scientific Statements & Platform for Belantamab Mafodotin Launch - Evidence Generation, Publication Planning and Life Cycle Management - Global Medical Engagement Plan creation & execution - Early Access Programme Strategy- Governance, concept & protocol review structure for Investigator Sponsored Studies (set up MRC, PRC across preclinical, clinical MM, other indications)- Led Medical Affairs set up of Cornea Health Plan- Established Global Patient Advocacy and Partnership relationships - Established Global Myeloma Council - Drove talent build across US and EU D5 to build best in class Medical Affairs Teams with Innovative Active Medical Mindset

Global Commercial Leader for highest growth brand in Novartis Oncology: Promacta/Revolade and delivered Blockbuster status in 2018 (35% YoY growth) - Executed roll out of fresh co-created content & revitalised promotional campaign: relaunching the brand across indications in US and oUS markets- Designed & rolled out new segmented Oncology Sales model for US, D5, JP- Led and managed cross-functional team to deliver the largest global patient survey ever conducted in ITP (I-WISh), addressing data gaps in HRQOL- Utilized strong external networks to drive early attitudinal segmentation and produce tailored, multi-channel segmented content for markets- Drove success by putting culture and people first: launched & embedded ‘Revolade Gateway’ global community- Drove and led Global Expert Panel to bring deep external insights and customer insights to sales force - Helped deliver launch excellence for sNDA in front line SAA (severe aplastic anaemia)- Led Competitive Intelligence effort across thrombocytopenia and helped shape BD&L strategy & pipeline assets for 10-year disease area strategy- Escalated simplification of global to country copy approval procedure, adopted Novartis Group wide- Led complex agency teams during ‘One agency’ transition to Havas and beyond to execution

• Driving force of cross-functional team contributing to highest growth brand in the UK Business• Executed first UK Real World Evidence study in Thrombopoeitin Receptor Agonists (TRAIT)• Produced high quality Masterclass meetings across the UK: winning UK team award for Performance• Medical Lead of Clinical Trials work stream for Novartis Patient Declaration• Collaborated across clinical and patient community to drive data generation and dissemination in ITP Globally• Led transition of ex-GSK Global CDP of eltrombopag to GMA, GVA and GDD stakeholders• Co-produced devolved nation HTAs for paediatric ITP • Member of change advisory board for UK Oncology Business Unit, winning team award for Courage• UK Medical Lead for ITP• Led Global Speaker Training• Prelaunch planning for Severe Aplastic Anaemia, Paediatric ITP• Led Cancer Drugs Fund negotiation for Nelarabine• Advisory Board and 1:1 planning and execution• Medical interface for Investigator Initiated and Novartis sponsored studies

Medical lead for UK Haematology portfolio involving eltrombopag and ofatumumab. Encompassing: 1. Successful HTA preparation for NICE and SMC2. Medical lead for the delivery of symposia and peer to peer exchange3. Launched Arzerra, ofatumumab in first line Chronic Lymphocytic Leukaemia4. External relationship prioritisation and transition to Novartis Oncology during divestment of GSK Oncology5. Medical lead for all UK Haematology Investigator Sponsored Studies6. Preparation and delivery of annual medical strategic plan

Founding member of commercialisation team, bringing an idea from bench to market in < 3 years.1. Bringing real time DNA sequencing technology to the customer interface2. Designed protocol and conducted two cosmeceutical trials at the Institute of Bio-Inspiring Technology, Imperial College. 3. Co-selected and investigated skin-ageing SNPs and their response to OTC cosmetic serums4. Developed photonumeric algorithm for facial wrinkling and standardised pigmentation score 5. Co-managed cosmeceutical claims and led cross-functional team in claims analysis6. Managed and led trial teams to deliver photographic, Dermatologist assessment and statistical analysis.

Dermatology Specialist training at King's College Hospital and St John's Institute of Dermatology, St Thomas' Hospital, London. 1. Management of acute and chronic cutaneous and systemic disease2. Biologic management of complex, inflammatory skin and joint disease3. Varied caseload from eczema, acne, rosacea and psoriasis to rarer immunobullous conditions, genodermatoses, infectious dermatology, and Mohs micrographic surgery for skin cancer4. Tertiary referral experience of advanced melanoma, cutaneous T-cell lymphoma and eczema. 5. Management of acute and complex tertiary referral patients with chronic plaque psoriasis and psoriatic arthritis requiring biologic, systemic and intensive topical therapy

4-monthly rotations across the following specialty areas: 1. Infectious Diseases2. Haematology3. Oncology4. Cardiology5. Respiratory 6. Rheumatology and Acute Medicine (West Middlesex Hospital)

4-monthly rotations across the following specialty areas: 1. Dermatology Research2. Critical Care Medicine3. Accident and Emergency Medicine

Pre-registration house office year rotating through: 1. Diabetes and Endocrinology2. Acute Medicine and Intensive Care3. Surgical Assessment Unit4. Colorectal surgery